Literature DB >> 17166394

The role of C-reactive protein in mood disorders.

D De Berardis1, D Campanella, F Gambi, R La Rovere, A Carano, C M Conti, C Sivestrini, N Serroni, D Piersanti, B Di Giuseppe, F S Moschetta, C Cotellessa, M Fulcheri, R M Salerno, F M Ferro.   

Abstract

Recently, a possible relationship between C-Reactive Protein (CRP), a marker of underlying low-grade inflammation, and mood disorders has been proposed by some researchers. The aim of this review is to elucidate the current facts and views about CRP in mood disorders such as Depressive and Bipolar Disorders. Several studies have examined the relationship between affective disorders and CRP, but the majority of the studies in literature have been limited by retrospective, case-controlled study design, and very few studies have examined the relationship between depression and CRP in large study samples. In conclusion, the role of CRP in mood disorders is, to date, intriguing but somewhat unclear. Further prospective studies are needed to introduce the CRP in clinical settings as a marker of affective states and suicidability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166394     DOI: 10.1177/039463200601900402

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  14 in total

Review 1.  Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Authors:  Heath D Schmidt; Richard C Shelton; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

Review 2.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

3.  Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk.

Authors:  Satish A Eraly; Caroline M Nievergelt; Adam X Maihofer; Donald A Barkauskas; Nilima Biswas; Agorastos Agorastos; Daniel T O'Connor; Dewleen G Baker
Journal:  JAMA Psychiatry       Date:  2014-04       Impact factor: 21.596

4.  Affective Disorders, Bone Metabolism, and Osteoporosis.

Authors:  Briana Mezuk
Journal:  Clin Rev Bone Miner Metab       Date:  2008-12

Review 5.  Protein biomarkers of mood disorders.

Authors:  Carmen Rodríguez Cerdeira; Elena Sánchez-Blanco; Beatriz Sánchez-Blanco; Jose Luis González-Cespón
Journal:  Int J Immunopathol Pharmacol       Date:  2017-01-24       Impact factor: 3.219

Review 6.  Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer's Disease Pathogenesis.

Authors:  Duraisamy Kempuraj; Govindhasamy P Selvakumar; Ramasamy Thangavel; Mohammad E Ahmed; Smita Zaheer; Sudhanshu P Raikwar; Shankar S Iyer; Sachin M Bhagavan; Swathi Beladakere-Ramaswamy; Asgar Zaheer
Journal:  Front Neurosci       Date:  2017-12-12       Impact factor: 4.677

Review 7.  Na⁺, K⁺-ATPase Signaling and Bipolar Disorder.

Authors:  David Lichtstein; Asher Ilani; Haim Rosen; Noa Horesh; Shiv Vardan Singh; Nahum Buzaglo; Anastasia Hodes
Journal:  Int J Mol Sci       Date:  2018-08-07       Impact factor: 5.923

Review 8.  Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome.

Authors:  Theoharis C Theoharides; Irene Tsilioni; Mona Bawazeer
Journal:  Front Cell Neurosci       Date:  2019-08-02       Impact factor: 5.505

Review 9.  Longitudinal association between CRP levels and risk of psychosis: a meta-analysis of population-based cohort studies.

Authors:  Emanuele F Osimo; Luke Baxter; Jan Stochl; Benjamin I Perry; Stephen A Metcalf; Setor K Kunutsor; Jari A Laukkanen; Marie Kim Wium-Andersen; Peter B Jones; Golam M Khandaker
Journal:  NPJ Schizophr       Date:  2021-05-28

10.  Scale-Up Synthesis and Identification of GLYX-13, a NMDAR Glycine-Site Partial Agonist for the Treatment of Major Depressive Disorder.

Authors:  Wenchao Li; Jingjian Liu; Minghua Fan; Zhongtang Li; Yin Chen; Guisen Zhang; Zhuo Huang; Liangren Zhang
Journal:  Molecules       Date:  2018-04-24       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.